Biological activity and pharmacokinetic profile of rifampicin incorporated into mucoadhesive crystal liquid precursor system in preclinical animal model of tuberculosis

• Grant number: 16/20622-4
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: February 26, 2017
• End date: February 25, 2018
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Marlus Chorilli
• Grantee: Kaio Pini Santos
• Supervisor: Mercedes Gonzalez Juarrero
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Institution abroad: Colorado State University, United States
• Associated to the scholarship: 15/00023-6 - Evaluation of the potential of mucoadhesive precursor systems of liquid crystals for nasal administration of rifampicin applicable on the optimization of tuberculosis therapy, BP.DR

Abstract

Tuberculosis (TB) is the main infectious disease of bacterial origin in the world. Since 1966,rifampicin (RIF) is the drug of choice used in the treatment of TB. Typically, the drug is administered orally, thus susceptible to pre-systemic metabolism and drug interactions with other drugs; this can lead to a decrease of the treatment effectiveness and to an increase on the risk of resistance. Thus, the use of nanostructured delivery systems and alternative routes of administration may be attractive strategies for the administration of RIF. The nasal route has received special attention as a promising route for systemic drug delivery, since it presents epithelium with numerous microvilli and large surface area, which facilitates the absorption ofdrugs. Among the promising nanostructured systems for RIF incorporation aiming nasaladministration, the mucoadhesive crystal liquid precursor systems (CLPS) are evidenced. Dueto the high viscosity of some areas of these systems, they can promote the fixation of theformulation to a desired site of action after administration, and in situ formation, which might be interesting for the administration of RIF to increase its attachment in the nasal region,facilitating its systemic absorption. On this project we will evaluate the activity of rifampic inincorporated into nanostructured system (liquid crystal) in preclinical animal model of tuberculosis and the pharmacokinetic profile of rifampicin incorporated into nanostructured system in in vivo model.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SANTOS, KAREN; LUKKA, PRADEEP B.; GRZEGORZEWICZ, ANNE; JACKSON, MARY; TRIVEDI, ASHIT; PAVAN, FERNANDO; CHORILLI, MARIUS; BRAUNSTEIN, MIRIAM; HICKEY, ANTHONY; MEIBOHM, BERND; et al. Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis. FRONTIERS IN MICROBIOLOGY, v. 9, AUG 21 2018. (16/20622-4)